{"entity":{"id":"paper-classic-5-year-follow-up-noh-lancet-oncol-2014","kind":"paper","name":"CLASSIC 5-year follow-up: adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy","aka":[],"tldr":"Five years on, the benefit of adjuvant capecitabine and oxaliplatin held and translated into longer survival: 78 percent alive against 69 percent with surgery alone.","summary":"Five-year follow-up of the CLASSIC trial (1,035 patients) at a median of 62.4 months: disease-free survival events in 27 percent of chemotherapy patients against 39 percent of observation patients (hazard ratio 0.58); estimated five-year disease-free survival 68 against 53 percent and overall survival 78 against 69 percent (hazard ratio 0.66).","asOf":"2026-09-22","links":[{"label":"Lancet Oncol 2014","url":"https://doi.org/10.1016/S1470-2045(14)70473-5"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/25439693/"}],"tags":[],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["capecitabine","oxaliplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["classic"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"journal":"The Lancet Oncology","year":2014,"doi":"10.1016/S1470-2045(14)70473-5","pmid":"25439693","authors":"Noh SH, Park SR, Yang HK, et al.","paperType":"rct","findings":["Five-year disease-free survival 68 percent (95% CI 63 to 73) versus 53 percent (47 to 58); hazard ratio 0.58 (0.47 to 0.72).","Five-year overall survival 78 percent (74 to 82) versus 69 percent (64 to 73); hazard ratio 0.66 (0.51 to 0.85), p 0.0015."],"whatItMeans":"Confirms a survival benefit for adjuvant CAPOX after D2 gastrectomy.","caveats":["Adverse event data were not collected after the primary analysis."],"changedPractice":true,"participants":1035},"route":"/key-papers/paper-classic-5-year-follow-up-noh-lancet-oncol-2014/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"}],"trial":[{"id":"classic","kind":"trial","name":"CLASSIC","route":"/trials/classic/"}],"journal":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}